# Elena Silvestri

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/elena-silvestri/

## Facts

| Field | Value |
| --- | --- |
| Citations | 3,902 |
| Field | Ocular Diseases and Behçet’s Syndrome |
| h-index | 38 |
| i10-index | 83 |
| Last Known Institution | University of Sannio |
| OpenAlex ID | https://openalex.org/A5035630918 |
| ORCID iD | 0000-0001-9719-2106 |
| Works | 138 |

## Researcher papers

- [Behçet's syndrome patients exhibit specific microbiome signature](https://scholariq.org/papers/behcet-s-syndrome-patients-exhibit-specific-microbiome-signature/)
- [Neutrophil Activation Promotes Fibrinogen Oxidation and Thrombus Formation in Behçet Disease](https://scholariq.org/papers/neutrophil-activation-promotes-fibrinogen-oxidation-and-thrombus-formation-in/)
- [Vascular Behçet’s syndrome: an update](https://scholariq.org/papers/vascular-behcet-s-syndrome-an-update/)
- [Thrombosis in vasculitis: from pathogenesis to treatment](https://scholariq.org/papers/thrombosis-in-vasculitis-from-pathogenesis-to-treatment/)
- [Thrombosis in inflammatory bowel diseases: what’s the link?](https://scholariq.org/papers/thrombosis-in-inflammatory-bowel-diseases-what-s-the-link/)
- [Response to Interleukin-1 Inhibitors in 140 Italian Patients with Adult-Onset Still’s Disease: A Multicentre Retrospective Observational Study](https://scholariq.org/papers/response-to-interleukin-1-inhibitors-in-140-italian-patients-with-adult-onset/)
- [Efficacy and safety profile of anti-interleukin-1 treatment in Behçet’s disease: a multicenter retrospective study](https://scholariq.org/papers/efficacy-and-safety-profile-of-anti-interleukin-1-treatment-in-behcet-s-disease/)
- [Brief Report: Rituximab for the Treatment of Adult‐Onset IgA Vasculitis (Henoch‐Schönlein)](https://scholariq.org/papers/brief-report-rituximab-for-the-treatment-of-adult-onset-iga-vasculitis-henoch/)
- [A Snapshot on the On-Label and Off-Label Use of the Interleukin-1 Inhibitors in Italy among Rheumatologists and Pediatric Rheumatologists: A Nationwide Multi-Center Retrospective Observational Study](https://scholariq.org/papers/a-snapshot-on-the-on-label-and-off-label-use-of-the-interleukin-1-inhibitors-in/)
- [Safety profile of the interleukin-1 inhibitors anakinra and canakinumab in real-life clinical practice: a nationwide multicenter retrospective observational study](https://scholariq.org/papers/safety-profile-of-the-interleukin-1-inhibitors-anakinra-and-canakinumab-in-real/)
- [Non-anti TNFα biologic agents for noninfectious uveitis associated with systemic inflammatory diseases: a systematic review](https://scholariq.org/papers/non-anti-tnf-biologic-agents-for-noninfectious-uveitis-associated-with-systemic/)

## Researcher topics

- [Ocular Diseases and Behçet’s Syndrome](https://scholariq.org/topics/ocular-diseases-and-behcet-s-syndrome/)
- [Systemic Lupus Erythematosus Research](https://scholariq.org/topics/systemic-lupus-erythematosus-research/)
- [Vasculitis and related conditions](https://scholariq.org/topics/vasculitis-and-related-conditions/)
- [Autoimmune and Inflammatory Disorders Research](https://scholariq.org/topics/autoimmune-and-inflammatory-disorders-research/)
- [Otitis Media and Relapsing Polychondritis](https://scholariq.org/topics/otitis-media-and-relapsing-polychondritis/)

## Researcher university

- [University of Sannio](https://scholariq.org/institutions/university-of-sannio/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.